<DOC>
	<DOCNO>NCT00566384</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness study drug libido ( sexual desire ) woman take oral contraceptive experience libido reduction side-effect contraceptive method The hypothesis superiority change sexual desire arousal component score FSFI questionnaire baseline cycle 6 treatment study drug compare Placebo .</brief_summary>
	<brief_title>Efficacy Safety Oral Dehydroepiandrosterone Concomitant Therapy Oral Contraceptives Women Complaining Reduced Libido</brief_title>
	<detailed_description />
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Treatment oral contraceptive ( OC ) least 3 month willing continue OC Loss libido Sexual relationship sexually competent partner Female sexual dysfunction HSDD , arousal orgasmic disorder , sexual aversion/phobic disorder , sexual pain disorder/dyspareunia Hyperandrogenemic condition , congenital adrenal hyperplasia ( CAH ) , polycystic ovary syndrome ( PCOS ) , Cushing 's syndrome sign hyperandrogenism like severe hirsutism severe acne Presence history venous arterial thrombotic/thromboembolic event ( e.g. , deep venous thrombosis , pulmonary embolism , myocardial infarction ) cerebrovascular accident . Presence history prodromi thrombosis ( e.g. , transient ischaemic attack , angina pectoris ) . History migraine focal neurological symptom . Diabetes mellitus vascular involvement . Presence severe multiple risk factor ( ) venous arterial thrombosis Pancreatitis history thereof associate severe hypertriglyceridemia Presence history severe hepatic disease long liver function value return normal . Presence history liver tumor ( benign malignant ) . Known suspected sexsteroid influence malignancy ( e.g. , genital organ breast ) Undiagnosed vaginal bleeding . Known suspected pregnancy . Hypersensitivity active substance excipients . Bodymass index ( BMI ) 30.0 kg/mÂ² Hypersensitivity study drug ingredient Any disease condition compromise function body system could result altered absorption , excessive accumulation , impaired metabolism , alter excretion study medication Known current history alcohol drug abuse Prohibited concomitant medication : Use additional steroid hormone , anticoagulant ( e.g. , heparin , coumarin ) , antiepileptic ( hydantoin derivates , e.g. , phenytoin carboxamide derivates , e.g. , carbamazepin , oxcarbamazepin ) , antiepileptic , ( e.g. , Felbamate , Topiramate ) , hypnotic sedative ( e.g. , barbiturate derivates , primidone ) , tuberculostatics ( e.g. , rifampicin ) , oral antimycotic ( e.g. , griseofulvin , ketoconazole , itraconazole , fluconazol ) , virostatic agent ( e.g. , ritonavir ) , product contain St. John 's wort continuous systemic use antibiotic . Medication influence libido ( e.g. , antihypertensive like betaadrenergic blocker , cholinesterase block agent ) , psychotropic drug ( e.g. , antidepressant , neuroleptic agent , selective serotonin reuptake inhibitor [ SSRIs ] ) , lipid lower drug H2 blocker . Intake experimental drug within 3 month prior inclusion study Previous assignment treatment ( e.g. , randomization ) study Close affiliation investigational site ; e.g. , close relative investigator , dependent person ( e.g. , employee student investigational site ) . Operation schedule study period Abnormal laboratory value within noninclusion range Patient custody order authority court law</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Loss libido</keyword>
	<keyword>Acquired , oral contraceptive -associated female sexual dysfunction</keyword>
</DOC>